Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Bladder Cancer, November 2017

Free Subscription


Abstracts

Retrieve all available abstracts of the following 134 articles:
HTML format


 

Single Articles

  1. MAO XW, Xiao JQ, Xu G, Li ZY, et al
    CUL4B promotes bladder cancer metastasis and induces epithelial-to-mesenchymal transition by activating the Wnt/beta-catenin signaling pathway.
    Oncotarget. 2017;8:77241-77253.
    Abstract    

    Abstract available

  2. ZHAN Y, Li Y, Guan B, Wang Z, et al
    Long non-coding RNA HNF1A-AS1 promotes proliferation and suppresses apoptosis of bladder cancer cells through upregulating Bcl-2.
    Oncotarget. 2017;8:76656-76665.
    Abstract    

    Abstract available

  3. AL-AMER M, Abdeen Y, Shaaban H, Alderink C, et al
    Solitary pulmonary adenofibroma in a middle-aged man with bladder cancer.
    Lung India. 2017;34:570-572.
    Abstract    



  4. NIWA N, Kikuchi E, Matsumoto K, Kosaka T, et al
    Purified protein derivative skin test reactions are associated with clinical outcomes of patients with nonmuscle invasive bladder cancer treated with induction bacillus Calmette-Guerin therapy.
    Urol Oncol. 2017 Oct 30. pii: S1078-1439(17)30535.
    Abstract    

    Abstract available

  5. DEGEORGE KC, Holt HR, Hodges SC
    Bladder Cancer: Diagnosis and Treatment.
    Am Fam Physician. 2017;96:507-514.
    Abstract    

    Abstract available

  6. WALSHAW RC, Honeychurch J, Illidge TM, Choudhury A, et al
    The anti-PD-1 era - an opportunity to enhance radiotherapy for patients with bladder cancer.
    Nat Rev Urol. 2017 Oct 31. doi: 10.1038/nrurol.2017.
    Abstract    

    Abstract available

  7. GORDON PC, Thomas F, Noon AP, Rosario DJ, et al
    Long-term Outcomes from Re-resection for High-risk Non-muscle-invasive Bladder Cancer: A Potential to Rationalize Use.
    Eur Urol Focus. 2017 Oct 28. pii: S2405-4569(17)30241.
    Abstract    

    Abstract available

  8. LIU J, Gong X, Zhu X, Xue D, et al
    Rab27A overexpression promotes bladder cancer proliferation and chemoresistance through regulation of NF-kappaB signaling.
    Oncotarget. 2017;8:75272-75283.
    Abstract    

    Abstract available

  9. SATO M, Yoneyama MS, Hatakeyama S, Funyu T, et al
    The role of LIM and SH3 protein-1 in bladder cancer metastasis.
    Oncol Lett. 2017;14:4829-4834.
    Abstract    

    Abstract available

  10. ZHUANG C, Huang X, Zhuang C, Luo X, et al
    Synthetic regulatory RNAs selectively suppress the progression of bladder cancer.
    J Exp Clin Cancer Res. 2017;36:151.
    Abstract    

    Abstract available

  11. TAN DQ, Liu XH
    [Mechanism in growth inhibition of quercetin on human bladder cancer cell line].
    Zhongguo Zhong Yao Za Zhi. 2017;42:1742-1746.
    Abstract    

    Abstract available

  12. MITRAKAS L, Gravas S, Papandreou C, Koukoulis G, et al
    Primary High-Grade Non-Muscle-Invasive Bladder Cancer: High NFkappaB Expression in Tumor Specimens Distinguishes Patients Who are at Risk for Disease Progression.
    Pathol Oncol Res. 2017 Oct 28. doi: 10.1007/s12253-017-0340.
    Abstract    

    Abstract available

  13. LIN T, Li K, Liu H, Xue X, et al
    Enhanced recovery after surgery for radical cystectomy with ileal urinary diversion: a multi-institutional, randomized, controlled trial from the Chinese bladder cancer consortium.
    World J Urol. 2017 Oct 28. doi: 10.1007/s00345-017-2108.
    Abstract    

    Abstract available

  14. HENRY CJ, Flesner BK, Bechtel SA, Bryan JN, et al
    Clinical Evaluation of Tavocept to Decrease Diuresis Time and Volume in Dogs with Bladder Cancer Receiving Cisplatin.
    J Vet Intern Med. 2017 Oct 27. doi: 10.1111/jvim.14848.
    Abstract    

    Abstract available

  15. CHOUDHARY D, Clement JM, Choudhary S, Voznesensky O, et al
    SATB1 and bladder cancer: Is there a functional link?
    Urol Oncol. 2017 Oct 24. pii: S1078-1439(17)30531.
    Abstract    

    Abstract available

  16. LYNCH HN, Zu K, Kennedy EM, Lam T, et al
    Corrigendum to "Quantitative assessment of lung and bladder cancer risk and oral exposure to inorganic arsenic: Meta-regression analyses of epidemiological data" Environmental International 106 :178-206.
    Environ Int. 2017;109:195-196.
    Abstract    



  17. LEIVO MZ, Sahoo D, Hamilton Z, Mirsadraei L, et al
    Analysis of T1 Bladder Cancer on Biopsy and Transurethral Resection Specimens: Comparison and Ranking of T1 Quantification Approaches to Predict Progression to Muscularis Propria Invasion.
    Am J Surg Pathol. 2017 Oct 26. doi: 10.1097/PAS.0000000000000964.
    Abstract    

    Abstract available

  18. LIN YC, Lin JF, Tsai TF, Chen HE, et al
    Acridine orange exhibits photodamage in human bladder cancer cells under blue light exposure.
    Sci Rep. 2017;7:14103.
    Abstract    

    Abstract available

  19. HENDRICKSEN K, Aziz A, Bes P, Chun FK, et al
    Discrepancy Between European Association of Urology Guidelines and Daily Practice in the Management of Non-muscle-invasive Bladder Cancer: Results of a European Survey.
    Eur Urol Focus. 2017 Oct 23. pii: S2405-4569(17)30206.
    Abstract    

    Abstract available

  20. LI QQ, Hsu I, Sanford T, Railkar R, et al
    Protein kinase D inhibitor CRT0066101 suppresses bladder cancer growth in vitro and xenografts via blockade of the cell cycle at G2/M.
    Cell Mol Life Sci. 2017 Oct 25. doi: 10.1007/s00018-017-2681.
    Abstract    

    Abstract available

  21. ZAHRAN MH, Sheir K, Zidan EM, Ali-El-Dein B, et al
    Validation of the Arabic version of the Functional Assessment of Cancer Therapy-Bladder questionnaire in Egyptian patients with bladder cancer.
    Arab J Urol. 2017;15:110-114.
    Abstract    

    Abstract available

  22. AHN KI, Choi EO, Kwon DH, HwangBo H, et al
    Induction of apoptosis by ethanol extract of Citrus unshiu Markovich peel in human bladder cancer T24 cells through ROS-mediated inactivation of the PI3K/Akt pathway.
    Biosci Trends. 2017 Oct 24. doi: 10.5582/bst.2017.01218.
    Abstract    

    Abstract available

  23. TAO T, He C, Deng J, Huang Y, et al
    A novel synthetic derivative of quercetin, 8-trifluoromethyl-3,5,7,3',4'-O-pentamethyl-quercetin, inhibits bladder cancer growth by targeting the AMPK/mTOR signaling pathway.
    Oncotarget. 2017;8:71657-71671.
    Abstract    

    Abstract available

  24. YIN H, Yang X, Gu W, Liu Y, et al
    HMGB1-mediated autophagy attenuates gemcitabine-induced apoptosis in bladder cancer cells involving JNK and ERK activation.
    Oncotarget. 2017;8:71642-71656.
    Abstract    

    Abstract available

  25. ROBERTS KJ, Kershner AM, Beachy PA
    The Stromal Niche for Epithelial Stem Cells: A Template for Regeneration and a Brake on Malignancy.
    Cancer Cell. 2017;32:404-410.
    Abstract    

    Abstract available

  26. HATA S, Ise K, Azmahani A, Konosu-Fukaya S, et al
    Expression of AR, 5alphaR1 and 5alphaR2 in bladder urothelial carcinoma and relationship to clinicopathological factors.
    Life Sci. 2017;190:15-20.
    Abstract    

    Abstract available

  27. PINK M, Verma N, Zerries A, Schmitz-Spanke S, et al
    Dose-Dependent Response to 3-Nitrobenzanthrone Exposure in Human Urothelial Cancer Cells.
    Chem Res Toxicol. 2017;30:1855-1864.
    Abstract    

    Abstract available

  28. HODGKINSON L
    American Urological Association (AUA) - 112th Annual Meeting (May 12-16, 2017 - Boston, Massachusetts, USA).
    Drugs Today (Barc). 2017;53:367-369.
    Abstract    

    Abstract available

  29. JIKUYA R, Washimi K, Yasui M, Hashizume A, et al
    [A Case of Long Survival in Aggressively Growing Small Cell Carcinoma of the Bladder Successfully Treated by Combined Chemotherapy of Methotrexate, Etoposide and Cisplatin].
    Hinyokika Kiyo. 2017;63:245-249.
    Abstract    

    Abstract available

  30. STEENLAND K, Barry V, Anttila A, Sallmen M, et al
    A cohort mortality study of lead-exposed workers in the USA, Finland and the UK.
    Occup Environ Med. 2017;74:785-791.
    Abstract    

    Abstract available

  31. YAMADA M, Kuroda H, Sato K, Miura S, et al
    Spontaneous regression of methotrexate-related diffuse large B-cell lymphoma following bladder lesion resection.
    Rinsho Ketsueki. 2017;58:287-291.
    Abstract    

    Abstract available

  32. HUHE M, Liu S, Zhang Y, Zhang Z, et al
    Expression levels of transcription factors c-Fos and c-Jun and transmembrane protein HAb18G/CD147 in urothelial carcinoma of the bladder.
    Mol Med Rep. 2017;15:2991-3000.
    Abstract    

    Abstract available

  33. BUTT E, Ebbing J, Bubendorf L, Ardelt P, et al
    Influence of hematuria and infection on diagnostic accuracy of urinary LASP1: a new biomarker for bladder carcinoma.
    Biomark Med. 2017;11:347-357.
    Abstract    

    Abstract available

  34. ALANEE SR, Shah S, Zabor EC, Vijai J, et al
    Evaluating the association of multiple single nucleotide polymorphisms with response to gemcitabine and platinum combination chemotherapy in urothelial carcinoma of the bladder.
    Int J Clin Pharmacol Ther. 2017;55:203-209.
    Abstract    

    Abstract available

  35. MAUGERI R, Graziano F, Basile L, Guli C, et al
    Reconstruction of Vertebral Body After Radiofrequency Ablation and Augmentation in Dorsolumbar Metastatic Vertebral Fracture: Analysis of Clinical and Radiological Outcome in a Clinical Series of 18 Patients.
    Acta Neurochir Suppl. 2017;124:81-86.
    Abstract    

    Abstract available

  36. KRAJEWSKI W, Koscielska-Kasprzak K, Rymaszewska J, Zdrojowy R, et al
    How different cystoscopy methods influence patient sexual satisfaction, anxiety, and depression levels: a randomized prospective trial.
    Qual Life Res. 2017;26:625-634.
    Abstract    

    Abstract available

  37. XU ZQ, Yang MG, Liu HJ, Su CQ, et al
    Circular RNA hsa_circ_0003221 (circPTK2) promotes the proliferation and migration of bladder cancer cells.
    J Cell Biochem. 2017 Nov 10. doi: 10.1002/jcb.26492.
    Abstract    

    Abstract available

  38. PAQUETTE M, Vilera-Perez LG, Beaudoin S, Ekindi-Ndongo N, et al
    Targeting IL-5Ralpha with antibody-conjugates reveals a strategy for imaging and therapy for invasive bladder cancer.
    Oncoimmunology. 2017;6:e1331195.
    Abstract    

    Abstract available

  39. CASADEVALL D, Kilian AY, Bellmunt J
    The prognostic role of epigenetic dysregulation in bladder cancer: A systematic review.
    Cancer Treat Rev. 2017;61:82-93.
    Abstract    

    Abstract available

  40. SHEGAY PV, Zhavoronkov AA, Gaifullin NM, Vorob'ev NV, et al
    Potentialities of MicroRNA Diagnosis in Patients with Bladder Cancer.
    Bull Exp Biol Med. 2017 Nov 9. doi: 10.1007/s10517-017-3935.
    Abstract    

    Abstract available

  41. KOCHAN A, Rivest R, Galloway K, Lambert P, et al
    Targeting the Tumor: Assessing the Impact of Bladder Volume and Position on Accuracy of Radiation Delivery for Patients with Bladder Cancer.
    Cureus. 2017;9:e1638.
    Abstract    

    Abstract available

  42. RUTHERFORD C, King MT, Smith DP, Costa DS, et al
    Psychometric Evaluation of a Patient-Reported Symptom Index for Nonmuscle Invasive Bladder Cancer: Field Testing Protocol.
    JMIR Res Protoc. 2017;6:e216.
    Abstract    

    Abstract available

  43. BERDIK C
    Unlocking bladder cancer.
    Nature. 2017;551:S34-S35.
    Abstract    



  44. BERDIK C
    Bladder cancer: 4 big questions.
    Nature. 2017;551:S51.
    Abstract    



  45. GRAYSON M
    Bladder cancer.
    Nature. 2017;551:S33.
    Abstract    



  46. ZHANG J, Zhu Y, Wang Y, Fu Q, et al
    Prognostic and Predictive Value of O6-methylguanine Methyltransferase for Chemotherapy in Patients with Muscle-Invasive Bladder Cancer.
    Ann Surg Oncol. 2017 Nov 7. doi: 10.1245/s10434-017-6145.
    Abstract    

    Abstract available

  47. LI Q, Tang T, Zhang P, Liu C, et al
    Correlation of IL-31 gene polymorphisms with susceptibility and clinical recurrence of bladder cancer.
    Fam Cancer. 2017 Nov 8. doi: 10.1007/s10689-017-0060.
    Abstract    

    Abstract available

  48. FREES SK, Aning J, Black P, Struss W, et al
    A prospective randomized pilot study evaluating an ERAS protocol versus a standard protocol for patients treated with radical cystectomy and urinary diversion for bladder cancer.
    World J Urol. 2017 Nov 7. doi: 10.1007/s00345-017-2109.
    Abstract    

    Abstract available

  49. SATO T, Katsuoka Y, Yoneda K, Nonomura M, et al
    Sniffer mice discriminate urine odours of patients with bladder cancer: A proof-of-principle study for non-invasive diagnosis of cancer-induced odours.
    Sci Rep. 2017;7:14628.
    Abstract    

    Abstract available

  50. DEININGER S, Todenhofer T, Hennenlotter J, Gerber V, et al
    Impact of variant microscopic interpretation of the uCyt+ immunocytological urine test for the detection of bladder cancer.
    Diagn Cytopathol. 2017 Nov 8. doi: 10.1002/dc.23857.
    Abstract    

    Abstract available

  51. POUPEL F, Aghaei M, Movahedian A, Jafari SM, et al
    Dihydroartemisinin Induces Apoptosis in Human Bladder Cancer Cell Lines Through Reactive Oxygen Species, Mitochondrial Membrane Potential, and Cytochrome C Pathway.
    Int J Prev Med. 2017;8:78.
    Abstract    

    Abstract available

  52. KIM HS, Jeong CW, Kwak C, Kim HH, et al
    Adjuvant chemotherapy for muscle-invasive bladder cancer: a systematic review and network meta-analysis of randomized clinical trials.
    Oncotarget. 2017;8:81204-81214.
    Abstract    

    Abstract available

  53. ZHANG C, Wang YQ, Jin G, Wu S, et al
    Selection of reference genes for gene expression studies in human bladder cancer using SYBR-Green quantitative polymerase chain reaction.
    Oncol Lett. 2017;14:6001-6011.
    Abstract    

    Abstract available

  54. LUO J, Chen J, Li H, Yang Y, et al
    LncRNA UCA1 promotes the invasion and EMT of bladder cancer cells by regulating the miR-143/HMGB1 pathway.
    Oncol Lett. 2017;14:5556-5562.
    Abstract    

    Abstract available

  55. CHEN Y, Wang H, Xiong T, Zou R, et al
    The role of LASS2 in regulating bladder cancer cell tumorigenicity in a nude mouse model.
    Oncol Lett. 2017;14:5149-5156.
    Abstract    

    Abstract available

  56. ICHIKAWA H, Itsumi M, Kajioka S, Maki T, et al
    Overexpression of exchange protein directly activated by cAMP-1 (EPAC1) attenuates bladder cancer cell migration.
    Biochem Biophys Res Commun. 2017 Oct 27. pii: S0006-291X(17)32127.
    Abstract    

    Abstract available

  57. AEISHEN S, Dawood Y, Papadoukakis S, Horstmann M, et al
    [Supplementary optical techniques for the detection of nonmuscle invasive bladder cancer].
    Urologe A. 2017 Nov 6. doi: 10.1007/s00120-017-0539.
    Abstract    

    Abstract available

  58. LEBENTRAU S, May M, Wick AK, Roiner M, et al
    Non-muscle invasive bladder cancer: Are epicrises the 'Bermuda Triangle' of information transfer?
    Cent European J Urol. 2017;70:245-251.
    Abstract    

    Abstract available

  59. FAHMY O, Khairul-Asri MG, Schubert T, Renninger M, et al
    A systematic review and meta-analysis on the oncological long-term outcomes after trimodality therapy and radical cystectomy with or without neoadjuvant chemotherapy for muscle-invasive bladder cancer.
    Urol Oncol. 2017 Oct 25. pii: S1078-1439(17)30529.
    Abstract    

    Abstract available

  60. LIM-REINDERS S, Keller BM, Al-Ward S, Sahgal A, et al
    Online Adaptive Radiation Therapy.
    Int J Radiat Oncol Biol Phys. 2017;99:994-1003.
    Abstract    

    Abstract available

  61. NEUZILLET Y, Raynaud JP, Radulescu C, Fiet J, et al
    Sexual steroids in serum and prostatic tissue of human non-cancerous prostate (STERPROSER trial).
    Prostate. 2017;77:1512-1519.
    Abstract    

    Abstract available

  62. KOK HP, Korshuize-van Straten L, Bakker A, de Kroon-Oldenhof R, et al
    Online Adaptive Hyperthermia Treatment Planning During Locoregional Heating to Suppress Treatment-Limiting Hot Spots.
    Int J Radiat Oncol Biol Phys. 2017;99:1039-1047.
    Abstract    

    Abstract available

  63. GLYBOCHKO PV, Alyaev YG, Shpot' EV, Pshi-Khachev AM, et al
    [Laparoscopic cystoprostatvesiculeectomy with orthotopic excentric ileal bladder substitution].
    Urologiia. 2017;:78-83.
    Abstract    

    Abstract available

  64. ROBSAHM TE, Falk RS, Heir T, Sandvik L, et al
    Cardiorespiratory fitness and risk of site-specific cancers: a long-term prospective cohort study.
    Cancer Med. 2017;6:865-873.
    Abstract    

    Abstract available

  65. RAMOS JD, Casey MF, Crabb SJ, Bamias A, et al
    Venous thromboembolism in metastatic urothelial carcinoma or variant histologies: incidence, associative factors, and effect on survival.
    Cancer Med. 2017;6:186-194.
    Abstract    

    Abstract available

  66. BREYER J, Wirtz RM, Otto W, Erben P, et al
    High PDL1 mRNA expression predicts better survival of stage pT1 non-muscle-invasive bladder cancer (NMIBC) patients.
    Cancer Immunol Immunother. 2017 Nov 17. doi: 10.1007/s00262-017-2093.
    Abstract    

    Abstract available

  67. QU H, Zheng Y, Wang Y, Zhang R, et al
    Global and Regional Effects of Bladder Cancer Risk Associated with Pioglitazone Therapy in Patients with Diabetes.
    Sci Rep. 2017;7:15804.
    Abstract    

    Abstract available

  68. POZZI V, Di Ruscio G, Sartini D, Campagna R, et al
    Clinical performance and utility of a NNMT-based urine test for bladder cancer.
    Int J Biol Markers. 2017 Nov 11:0. doi: 10.5301/ijbm.5000311.
    Abstract    

    Abstract available

  69. MARI A, Campi R, Tellini R, Gandaglia G, et al
    Patterns and predictors of recurrence after open radical cystectomy for bladder cancer: a comprehensive review of the literature.
    World J Urol. 2017 Nov 16. doi: 10.1007/s00345-017-2115.
    Abstract    

    Abstract available

  70. HU Q, Wang G, Peng J, Qian G, et al
    Knockdown of SIRT1 Suppresses Bladder Cancer Cell Proliferation and Migration and Induces Cell Cycle Arrest and Antioxidant Response through FOXO3a-Mediated Pathways.
    Biomed Res Int. 2017;2017:3781904.
    Abstract    

    Abstract available

  71. LE GOUX C, Vacher S, Pignot G, Sibony M, et al
    mRNA Expression levels of genes involved in antitumor immunity: Identification of a 3-gene signature associated with prognosis of muscle-invasive bladder cancer.
    Oncoimmunology. 2017;6:e1358330.
    Abstract    

    Abstract available

  72. DAVIDSON MB, Pan D
    An Updated Meta-Analysis of Pioglitazone Exposure and Bladder Cancer and Comparison to the Drug's Effect on Cardiovascular Disease and Non-Alcoholic Steatohepatitis.
    Diabetes Res Clin Pract. 2017 Nov 13. pii: S0168-8227(17)31438.
    Abstract    

    Abstract available

  73. NISHIYAMA H
    Asia Consensus Statement on NCCN Clinical Practice Guideline for bladder cancer.
    Jpn J Clin Oncol. 2017 Nov 14:1-4. doi: 10.1093.
    Abstract    

    Abstract available

  74. XU Y, Huo R, Chen X, Yu X, et al
    Diabetes mellitus and the risk of bladder cancer: A PRISMA-compliant meta-analysis of cohort studies.
    Medicine (Baltimore). 2017;96:e8588.
    Abstract    

    Abstract available

  75. HALSTEAD AM, Kapadia CD, Bolzenius J, Chu CE, et al
    Bladder cancer associated mutations in RXRA activate peroxisome proliferator-activated receptors to drive urothelial proliferation.
    Elife. 2017;6.
    Abstract    

    Abstract available

  76. ZHANG HH, Huang B, Cao YH, Li Q, et al
    Role of 5-Aza-CdR in mitomycin-C chemosensitivity of T24 bladder cancer cells.
    Oncol Lett. 2017;14:5652-5656.
    Abstract    

    Abstract available

  77. PENG C, Li A, Wang M
    Discovery of Bladder Cancer-related Genes Using Integrative Heterogeneous Network Modeling of Multi-omics Data.
    Sci Rep. 2017;7:15639.
    Abstract    

    Abstract available

  78. SMILOWITZ HM, Tarmu LJ, Sanders MM, Taylor JA 3rd, et al
    Biodistribution of gold nanoparticles in BBN-induced muscle-invasive bladder cancer in mice.
    Int J Nanomedicine. 2017;12:7937-7946.
    Abstract    

    Abstract available

  79. HURST CD, Alder O, Platt FM, Droop A, et al
    Genomic Subtypes of Non-invasive Bladder Cancer with Distinct Metabolic Profile and Female Gender Bias in KDM6A Mutation Frequency.
    Cancer Cell. 2017;32:701-715.
    Abstract    

    Abstract available

  80. MEEKS JJ, Lerner SP
    Molecular Landscape of Non-Muscle Invasive Bladder Cancer.
    Cancer Cell. 2017;32:550-551.
    Abstract    

    Abstract available

  81. STONE L
    Bladder cancer: Context is key: dual roles of ANGPTL4.
    Nat Rev Urol. 2017 Nov 14. doi: 10.1038/nrurol.2017.
    Abstract    



  82. FELSENSTEIN KM, Theodorescu D
    Precision medicine for urothelial bladder cancer: update on tumour genomics and immunotherapy.
    Nat Rev Urol. 2017 Nov 14. doi: 10.1038/nrurol.2017.
    Abstract    

    Abstract available

  83. LI HJ, Sun XM, Li ZK, Yin QW, et al
    LncRNA UCA1 Promotes Mitochondrial Function of Bladder Cancer via the MiR-195/ARL2 Signaling Pathway.
    Cell Physiol Biochem. 2017;43:2548-2561.
    Abstract    

    Abstract available

  84. LEIBLICH A
    Recent Developments in the Search for Urinary Biomarkers in Bladder Cancer.
    Curr Urol Rep. 2017;18:100.
    Abstract    

    Abstract available

  85. XIAN S, Shang D, Kong G, Tian Y, et al
    FOXJ1 promotes bladder cancer cell growth and regulates Warburg effect.
    Biochem Biophys Res Commun. 2017 Nov 9. pii: S0006-291X(17)32241.
    Abstract    

    Abstract available

  86. UNDA-URZAIZ M, Fernandez-Gomez JM, Cozar-Olmos JM, Juarez A, et al
    Update on the role of endovesical chemotherapy in nonmuscle-invasive bladder cancer.
    Actas Urol Esp. 2017 Nov 9. pii: S0210-4806(17)30180.
    Abstract    



  87. HERMANS TJN, Voskuilen CS, van der Heijden MS, Schmitz-Drager BJ, et al
    Neoadjuvant treatment for muscle-invasive bladder cancer: The past, the present, and the future.
    Urol Oncol. 2017 Nov 8. pii: S1078-1439(17)30551.
    Abstract    

    Abstract available

  88. RODRIGUEZ FABA O, Palou J, Vila Reyes H, Guirado L, et al
    Treatment options and predictive factors for recurrence and cancer-specific mortality in bladder cancer after renal transplantation: A multi-institutional analysis.
    Actas Urol Esp. 2017 Nov 7. pii: S0210-4806(17)30176.
    Abstract    

    Abstract available

  89. LIU JY, Dai YB, Li X, Cao K, et al
    Solute carrier family 12 member 5 promotes tumor invasion/metastasis of bladder urothelial carcinoma by enhancing NF-kappaB/MMP-7 signaling pathway.
    Cell Death Dis. 2017;8:e2691.
    Abstract    

    Abstract available

  90. ISMAIL S, Karsenty G, Chartier-Kastler E, Cussenot O, et al
    Prevalence, management, and prognosis of bladder cancer in patients with neurogenic bladder: A systematic review.
    Neurourol Urodyn. 2017 Nov 23. doi: 10.1002/nau.23457.
    Abstract    

    Abstract available

  91. GULIA C, Baldassarra S, Signore F, Rigon G, et al
    Role of Non-Coding RNAs in the Etiology of Bladder Cancer.
    Genes (Basel). 2017;8.
    Abstract    

    Abstract available

  92. PRASANNA T, Craft P, Balasingam G, Haxhimolla H, et al
    Intravesical Gemcitabine versus Intravesical Bacillus Calmette-Guerin for the Treatment of Non-Muscle Invasive Bladder Cancer: An Evaluation of Efficacy and Toxicity.
    Front Oncol. 2017;7:260.
    Abstract    

    Abstract available

  93. GAN Y, He L, Yao K, Tan J, et al
    Knockdown of HMGN5 increases the chemosensitivity of human urothelial bladder cancer cells to cisplatin by targeting PI3K/Akt signaling.
    Oncol Lett. 2017;14:6463-6470.
    Abstract    

    Abstract available

  94. VIRANI NA, Davis C, McKernan P, Hauser P, et al
    Phosphatidylserine targeted single-walled carbon nanotubes for photothermal ablation of bladder cancer.
    Nanotechnology. 2017 Nov 21. doi: 10.1088/1361-6528.
    Abstract    

    Abstract available

  95. BONET M, Bonfill T, Nunez M, De Verdonces L, et al
    Curative radiation therapy for very elderly bladder cancer patients with localized disease.
    Clin Transl Oncol. 2017 Nov 20. doi: 10.1007/s12094-017-1804.
    Abstract    

    Abstract available

  96. DOMINGUEZ-ESCRIG JL, Peyronnet B, Seisen T, Bruins HM, et al
    Potential Benefit of Lymph Node Dissection During Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Systematic Review by the European Association of Urology Guidelines Panel on Non-muscle-invasive Bladder Cancer.
    Eur Urol Focus. 2017 Nov 17. pii: S2405-4569(17)30236.
    Abstract    

    Abstract available

  97. SMITH AB
    Recent developments in the management of bladder cancer: Introduction.
    Urol Oncol. 2017 Nov 17. pii: S1078-1439(17)30563.
    Abstract    

    Abstract available

  98. FERGUSON JE 3RD, Kamat AM
    It's all about the perspective: Removing bias when co-managing patients with high-grade T1 bladder cancer and localized prostate cancer-A competing risks analysis.
    Urol Oncol. 2017 Nov 17. pii: S1078-1439(17)30556.
    Abstract    

    Abstract available

  99. AGGEN DH, Drake CG
    Biomarkers for immunotherapy in bladder cancer: a moving target.
    J Immunother Cancer. 2017;5:94.
    Abstract    

    Abstract available

  100. ANAN G, Hatakeyama S, Fujita N, Iwamura H, et al
    Trends in neoadjuvant chemotherapy use and oncological outcomes for muscle-invasive bladder cancer in Japan: a multicenter study.
    Oncotarget. 2017;8:86130-86142.
    Abstract    

    Abstract available

  101. ECKE TH, Otto T
    Illumination of a Vision-How Arthur Rimbaud Will Give Us Motivation to Find New Input into Bladder Cancer Biomarker Research.
    Int J Mol Sci. 2017;18.
    Abstract    

    Abstract available

  102. ZAHOOR H, Elson P, Stephenson A, Haber GP, et al
    Patient Characteristics, Treatment Patterns and Prognostic Factors in Squamous Cell Bladder Cancer.
    Clin Genitourin Cancer. 2017 Oct 17. pii: S1558-7673(17)30311.
    Abstract    

    Abstract available

  103. MILBAR N, Kates M, Chappidi MR, Pederzoli F, et al
    Oncological Outcomes of Sequential Intravesical Gemcitabine and Docetaxel in Patients with Non-Muscle Invasive Bladder Cancer.
    Bladder Cancer. 2017;3:293-303.
    Abstract    

    Abstract available

  104. HAQUE W, Verma V, Butler EB, Teh BS, et al
    Chemotherapy Versus Chemoradiation for Node-Positive Bladder Cancer: Practice Patterns and Outcomes from the National Cancer Data Base.
    Bladder Cancer. 2017;3:283-291.
    Abstract    

    Abstract available

  105. MALONEY I, Parker DC, Cookson MS, Patel S, et al
    Bladder Cancer Recovery Pathways: A Systematic Review.
    Bladder Cancer. 2017;3:269-281.
    Abstract    

    Abstract available

  106. KOTI M, Xu AS, Ren KYM, Visram K, et al
    Tertiary Lymphoid Structures Associate with Tumour Stage in Urothelial Bladder Cancer.
    Bladder Cancer. 2017;3:259-267.
    Abstract    

    Abstract available

  107. MORAN GW, Li G, Robins DJ, Matulay JT, et al
    Systematic Review and Meta-Analysis on the Efficacy of Chemotherapy with Transurethral Resection of Bladder Tumors as Definitive Therapy for Muscle Invasive Bladder Cancer.
    Bladder Cancer. 2017;3:245-258.
    Abstract    

    Abstract available

  108. XIE H, Liao X, Chen Z, Fang Y, et al
    LncRNA MALAT1 Inhibits Apoptosis and Promotes Invasion by Antagonizing miR-125b in Bladder Cancer Cells.
    J Cancer. 2017;8:3803-3811.
    Abstract    

    Abstract available

  109. PICHLER R, Fritz J, Heidegger I, Oberaigner W, et al
    Gender-related Outcome in Bladder Cancer Patients undergoing Radical Cystectomy.
    J Cancer. 2017;8:3567-3574.
    Abstract    

    Abstract available

  110. XU XL, Ye YL, Wu ZM, He QM, et al
    Overexpression of PTK6 predicts poor prognosis in bladder cancer patients.
    J Cancer. 2017;8:3464-3473.
    Abstract    

    Abstract available

  111. YANG X, Yuan W, Tao J, Li P, et al
    Identification of circular RNA signature in bladder cancer.
    J Cancer. 2017;8:3456-3463.
    Abstract    

    Abstract available

  112. LIAW CC, Chuang CK, Chang YH, Liao TY, et al
    Bladder Urothelial Carcinoma with Peritoneal Involvement: Benefit of Continuous Maintenance Chemotherapy.
    Anticancer Res. 2017;37:6443-6451.
    Abstract    

    Abstract available

  113. HSU FT, Sun CC, Wu CH, Lee YJ, et al
    Regorafenib Induces Apoptosis and Inhibits Metastatic Potential of Human Bladder Carcinoma Cells.
    Anticancer Res. 2017;37:4919-4926.
    Abstract    

    Abstract available

  114. KINNEAR N, Smith R, Hennessey DB, Bolton D, et al
    Implementation rates of uro-oncology multidisciplinary meeting decisions.
    BJU Int. 2017;120 Suppl 3:15-20.
    Abstract    

    Abstract available


  115. Bladder cancer: diagnosis and management of bladder cancer: (c) NICE (2015) Bladder cancer: diagnosis and management of bladder cancer.
    BJU Int. 2017;120:755-765.
    Abstract    



  116. KASHIWAGI E, Inoue S, Mizushima T, Chen J, et al
    Prostaglandin receptors induce urothelial tumourigenesis as well as bladder cancer progression and cisplatin resistance presumably via modulating PTEN expression.
    Br J Cancer. 2017 Nov 9. doi: 10.1038/bjc.2017.
    Abstract    

    Abstract available

  117. DUEX JE, Owens C, Chauca-Diaz A, Dancik GM, et al
    Nuclear CD24 Drives Tumor Growth and Is Predictive of Poor Patient Prognosis.
    Cancer Res. 2017;77:4858-4867.
    Abstract    

    Abstract available

  118. MAIA MC, Grivas P, Agarwal N, Pal SK, et al
    Circulating Tumor DNA in Bladder Cancer: Novel Applications and Future Directions.
    Eur Urol. 2017 Oct 30. pii: S0302-2838(17)30902.
    Abstract    



  119. ABUFARAJ M, Dalbagni G, Daneshmand S, Horenblas S, et al
    The Role of Surgery in Metastatic Bladder Cancer: A Systematic Review.
    Eur Urol. 2017 Nov 6. pii: S0302-2838(17)30840.
    Abstract    

    Abstract available

  120. LINSCOTT JA, Smith AB, Sammon JD
    Re: Woonyoung Choi, Andrea Ochoa, David J. McConkey, et al. Genetic Alterations in the Molecular Subtypes of Bladder Cancer: Illustration in the Cancer Genome Atlas Dataset. Eur Urol 2017;72:354-65.
    Eur Urol. 2017 Nov 9. pii: S0302-2838(17)30971.
    Abstract    



  121. KIM CJ, Terado T, Tambe Y, Mukaisho KI, et al
    Anti-oncogenic activities of cyclin D1b siRNA on human bladder cancer cells via induction of apoptosis and suppression of cancer cell stemness and invasiveness.
    Int J Oncol. 2017 Nov 7. doi: 10.3892/ijo.2017.4194.
    Abstract    

    Abstract available

  122. LV XY, Ma L, Chen JF, Yu R, et al
    Knockdown of DUXAP10 inhibits proliferation and promotes apoptosis in bladder cancer cells via PI3K/Akt/mTOR signaling pathway.
    Int J Oncol. 2017 Nov 7. doi: 10.3892/ijo.2017.4195.
    Abstract    

    Abstract available

  123. TAN YG, Eu EWC, Huang HH, Lau WKO, et al
    High neutrophil-to-lymphocyte ratio predicts worse overall survival in patients with advanced/metastatic urothelial bladder cancer.
    Int J Urol. 2017 Nov 1. doi: 10.1111/iju.13480.
    Abstract    

    Abstract available

  124. YANG X, Shi L, Yi C, Yang Y, et al
    Astrocyte elevated gene-1 promotes invasion and epithelial-mesenchymal transition in bladder cancer cells through activation of signal transducer and activator of transcription 3.
    Int J Urol. 2017 Nov 8. doi: 10.1111/iju.13486.
    Abstract    

    Abstract available

  125. CHANG SS
    Re: Propensity Score Analysis of Radical Cystectomy versus Bladder-Sparing Trimodal Therapy in the Setting of a Multidisciplinary Bladder Cancer Clinic.
    J Urol. 2017;198:1208.
    Abstract    



  126. CASILLA-LENNON MM, Choi SK, Deal AM, Bensen JT, et al
    Financial Toxicity in Bladder Cancer Patients- Reasons for Delay in Care and Effect on Quality of Life.
    J Urol. 2017 Nov 16. pii: S0022-5347(17)77917-7. doi: 10.1016/j.juro.2017.
    Abstract    

    Abstract available

  127. KOUMPAN Y, Jaeger M, Mizubuti GB, Tanzola R, et al
    Spinal Anesthesia is Associated with Lower Recurrence Rates after Resection of Non-Muscle Invasive Bladder Cancer.
    J Urol. 2017 Nov 14. pii: S0022-5347(17)77909-8. doi: 10.1016/j.juro.2017.
    Abstract    

    Abstract available

  128. LONG X, Qi L, Zu X, Li Y, et al
    Prevention of Recurrent Bladder Tumors after Nephroureterectomy for Primary Upper Urinary Tract Urothelial Carcinoma: An Individualized Selection Strategy Based on Patient Risk Stratification Is Needed.
    Urol Int. 2017;98:312-319.
    Abstract    

    Abstract available

  129. WOLTERS M, Oelke M, Lutze B, Weingart M, et al
    Deep Surgical Site Infections after Open Radical Cystectomy and Urinary Diversion Significantly Increase Hospitalisation Time and Total Treatment Costs.
    Urol Int. 2017;98:268-273.
    Abstract    

    Abstract available

  130. GARRIDO-ABAD P, Diaz-Menendez A, Fernandez-Arjona M
    Bladder Herpes Infection in a Patient with Low-Grade Non-Muscle-Invasive Bladder Cancer.
    Urology. 2017 Nov 13. pii: S0090-4295(17)31175.
    Abstract    

    Abstract available

  131. MORA VIDAL R, Regufe da Mota S, Hayden A, Markham H, et al
    EGFR Family Inhibition Identifies P38 MAPK as a Potential Therapeutic Target in Bladder Cancer.
    Urology. 2017 Nov 15. pii: S0090-4295(17)31184.
    Abstract    

    Abstract available

  132. MIYAKE M, Morizawa Y, Hori S, Marugami N, et al
    Clinical impact of postoperative loss in psoas major muscle and nutrition index after radical cystectomy for patients with urothelial carcinoma of the bladder.
    BMC Cancer. 2017;17:237.
    Abstract    

    Abstract available

  133. TAN WS, Feber A, Dong L, Sarpong R, et al
    DETECT I & DETECT II: a study protocol for a prospective multicentre observational study to validate the UroMark assay for the detection of bladder cancer from urinary cells.
    BMC Cancer. 2017;17:767.
    Abstract    

    Abstract available

  134. TOLKACH Y, Stahl AF, Niehoff EM, Zhao C, et al
    YRNA expression predicts survival in bladder cancer patients.
    BMC Cancer. 2017;17:749.
    Abstract    

    Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design:


;